| Objective: To evaluate the feasibility of hypoxia PETCT imagingguided simultaneous integrated boost intensity modulated radiotherapy(IMRT) through investigate the dosimetric differences.Methods: This study retrospectively selected 5non-small cell lung cancer(NSCLC) patients with pathologically diagnosed, stage Ⅱ-Ⅲb, who had been underwent 18F-FDG PETCT and 18F-FMISO before treatment in the First Affiliated Hospital of Zheng Zhou University from 2014 to 2015.CT and 18F-FMISO PETCT were co-registered the same immobilization methods. Regions of elevated 18F-FMISO uptake(TMR1.3) within the GTV were defined as BTV. The conventional dose of 60 Gy delivered to the PGTV and larger dose of 72Gy、78Gy、84Gy delivered to the BTV in different plans with using an integrated boost. We compared dose distribution of PTV and PBTV(Dmax,Dmean, D02,D98 and D95),and organs at risk between different plans.Results: 1. Target:we were able to deliver a simultaneous modulated boost of 72 Gy、78 Gy、84 Gy to the BTV with Intensity Modulated Radiation Therapy(IMRT),and the dose distribution of PTV meet the request of radiotherapy treatment planning. 2. Organs at risk(OARs): the organs at risk, including lung, heart, esophagus and spinal cord meet the dosimetric limits and no significant difference compare with normal radiotherapy treatment planning(60Gy).Conclusions: It was entirely feasible to use the 18F-FMISO and PETCT guided IMRT to deliver a simultaneous modulated boost 72 Gy、78 Gy、84 Gy in non-small cell lung cancer. |
PDF Full Text Request